TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Señales de momentum (gestores comparables):
amplitud de titulares -8.3% ·
flujo de acciones -1.4% ·
nuevas posiciones netas -9.1%
— fórmula
Distribución amplia — caída de acciones y menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q1 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | — |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | — |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | — | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | — |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | — | −2 |
| Q2 2024 | 23 | — | 44.78M | $24.75B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 16.54M | +0.6% | $8.24B | 0.3% | ▲ Add | 2 | SEC ↗ |
| 2 | Capital World Investors ✦ | 11.06M | +17.3% | $5.50B | 0.9% | ▲ Add | 4 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 9.30M | -14.8% | $4.63B | 0.6% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (pasivo) | 8.13M | +3.4% | $4.03B | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (pasivo) | 6.19M | +2.2% | $3.08B | 0.4% | ▲ Add | 4 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 2.72M | +1.9% | $1.35B | 0.6% | ▲ Add | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 2.32M | -7.5% | $1.15B | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.60M | +11.8% | $794.03M | 0.2% | ▲ Add | 4 | SEC ↗ ×7 |
| 9 | Arrowstreet Capital ✦ | 655.94K | +77.6% | $326.39M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 10 | Baillie Gifford ✦ | 509.38K | -5.5% | $253.47M | 0.2% | ▼ Trim | 4 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 331.26K | -26.7% | $164.84M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 235.37K | -56.7% | $117.12M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 233.45K | -40.2% | $116.17M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 209.26K | -5.4% | $102.36M | 0.1% | ▼ Trim | 4 | SEC ↗ ×6 |
| 15 | Millennium Management ✦ | 188.47K | -45.0% | $93.79M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 155.24K | -14.4% | $77.25M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 120.57K | -64.5% | $60.00M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 18 | Markel Group ✦ | 45.00K | +9.5% | $22.39M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 38.80K | -0.8% | $19.31M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 38.34K | +30.6% | $19.08M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 21 | Dodge & Cox ✦ | 26.11K | -0.1% | $12.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 3.91K | -5.1% | $1.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Third Point | $182.08M | era 2.4% |
| Marshall Wace | $171.84M | era 0.2% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 24.30K acciones, $11,944 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 3.73K acc. · $2.29M
Officer · 400 acc. · $245,752
Officer, Director · 62 acc. · $38,982
Officer, Director · 33 acc. · $20,677
Officer, Director · 101 acc. · $63,166
Officer, Director · 79 acc. · $49,613
Officer, Director · 2.15K acc. · $1.35M
Officer, Director · 1.79K acc. · $1.12M
Officer, Director · 3.01K acc. · $1.89M
Officer, Director · 2.73K acc. · $1.71M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología